We’re pursuing every opportunity to develop and bring our investigational drugs to patients
OLORINAB
A drug candidate for the treatment of IBS pain
Olorinab is an oral, peripherally acting, nonopioid analgesic under investigation for the management of visceral pain in irritable bowel syndrome. Olorinab is being evaluated to determine its safety and whether it may have sustained efficacy due to full cannabinoid type 2 (CB2) agonist activity, with a low risk of psychoactive effects due to high selectivity for CB2 versus cannabinoid type 1.
Olorinab is an investigational drug and is not currently approved for use by any health authority. This information is not intended to promote or recommend olorinab for any use.
Olorinab clinical trial program
CAPTIVATE is a Phase 2 clinical trial evaluating the efficacy and safety of oral olorinab in patients experiencing abdominal pain associated with irritable bowel syndrome (IBS).
ClinicalTrials.gov: NCT04043455Olorinab key references
Olorinab (APD371), a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2), reduces colitis-induced visceral hypersensitivity in rats
IASP, 2018
APD371: a potent, highly selective, full agonist of the human CB2 receptor with sustained analgesic effects in rodents
APS, 2018Discovery of APD371: identification of a highly potent and selective CB2 agonist for the treatment of chronic pain
ACS Med Chem Lett, 2017Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB2), reduces visceral hypersensitivity in animal models
DDW, 2019Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD)—preclinical and early clinical development
Crohn's & Colitis Congress, 2019Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), reduces visceral hypersensitivity in mice
DDW, 2020Expression and localization of cannabinoid receptors and the effect of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, on visceral hypersensitivity in rodent models of irritable bowel syndrome and inflammatory bowel disease
UEG, 2020Cannabinoid receptor 2 (CB2) localization in colonic tissue and primary sensory dorsal root ganglia (DRG) neurons isolated from rodents with colitis and chronic visceral hypersensitivity
DDW, 2021Safety and efficacy of olorinab, a peripherally acting, highly selective, cannabinoid type 2 receptor agonist in a phase 2a study in chronic abdominal pain associated with Crohn’s disease
DDW, 2019Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2a study in chronic abdominal pain associated with Crohn’s disease
ECCO, 2019Preclinical and clinical efficacy of olorinab, a peripherally restricted, highly selective full agonist of the cannabinoid receptor 2 for the management of visceral pain in inflammatory bowel disease
UEG, 2019Safety, tolerability, and pharmacokinetics of APD371, a highly selective CB₂ agonist, in healthy adults
APS, 2018
